The Infectious Diseases Society of America (IDSA) updated its COVID-19 treatment guidelines to include the monoclonal antibody (mAb) pemivibart (Pemgarda, Invivyd), the only FDA-authorized pre-exposure prophylaxis for COVID-19, which was granted emergency use authorization (EUA) in March for people who are immunocompromised (Clin Infect Dis 2024;78[7]:e250-e349) because they are at a greater risk for hospitalization, mechanical ventilation or death from COVID-19.
The guideline